Home / Products / Antibiotics / AEROFLOX 200
Click image to inspect pack details
Antibiotics Marketed by Aerochem Neutron

AEROFLOX 200

Formulation Code AC-384
Commercial Status Active Product Information Available

Product Overview & Formulation Profile

Description

Ofloxacin Tablets 200 mg

AEROFLOX 200 contains ofloxacin, an oral fluoroquinolone antibiotic used in the treatment of selected bacterial infections caused by susceptible organisms.

Ofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and maintenance. This action interferes with bacterial multiplication and produces a bactericidal effect.

Its clinical use depends on the site and severity of infection, the suspected or confirmed organism, local resistance patterns and patient-specific risk factors. Treatment should follow the approved prescribing information and current antibiotic stewardship recommendations.

Dosage Form: Tablets
Strength: 200 mg
Packing: 10 x 10 Alu Alu

Prescription medicine. Use only under medical supervision.

Composition & Formulation Details

Features

  • Fluoroquinolone antibiotic: An oral antibacterial agent used against susceptible bacterial pathogens.

  • Bactericidal action: Inhibits bacterial DNA gyrase and topoisomerase IV.

  • Antibacterial activity: Active against selected Gram-negative and Gram-positive organisms, depending on susceptibility.

  • Oral formulation: Provides a tablet dosage form where oral therapy is clinically appropriate.

  • Responsible prescribing: Selection requires consideration of antimicrobial resistance, alternative treatments and fluoroquinolone safety risks.

Conditions

Therapeutic areas — subject to confirmation against the approved Indian product label:

  • Selected urinary tract bacterial infections.

  • Certain respiratory tract bacterial infections.

  • Selected skin and soft-tissue bacterial infections.

Ofloxacin should be used only where clinically appropriate, with consideration of safer effective alternatives, individual risk factors and current treatment guidelines.

Important Safety Information

Fluoroquinolones, including ofloxacin, are associated with potentially serious adverse reactions involving tendons, peripheral nerves and the central nervous system. They may also worsen muscle weakness in patients with myasthenia gravis.

The full approved prescribing information must be consulted before treatment.

Professional Product Enquiries

Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.

Product Information

Review verified active composition, strength, dosage form, and packaging details on this page.

View Specifications

Healthcare Professional Enquiry

Request formulation literature, technical specifications, or product communication from our commercial team.

Submit Product Enquiry

Commercial Supply Enquiry

Connect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.

Commercial Enquiry

Professional Product Information

This product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.

Product Enquiry

Request Formulation Details

Request information about AEROFLOX 200 for professional use.

Please enter the numeric sum to verify you are a human visitor.
Approved Resources

Distributor Media

Product Image - AEROFLOX 200
Product Image

AEROFLOX 200 — Product Image

Therapeutic Alternatives

Related Formulations

SULTAVIN Formulation
AEROCLAV -625 Formulation
A.G 250 Formulation
PROXINA-CL Formulation
Product Information

Need specifications for this formulation?

Request verified product information for professional use, or send a separate business enquiry for manufacturing or partnership discussions.

WhatsApp: +91 9512047000